Improving Research to Build a Brighter Future for People with Hematologic Conditions

Individuals living with hematologic conditions need more evidence-based options for managing their health and improving their quality of life. The ASH Research Collaborative™ (ASH RC) is working to accelerate change by making it more efficient to conduct research, from increasing access to high-quality clinical data to making it easier for individuals with hematologic conditions to participate in studies.

Current ASH RC initiatives focus on multiple myeloma and sickle cell disease (SCD) clinical research.

The Data Hub will be the largest shared information resource with real-world data to serve the hematology community. Access to these data can accelerate research and development, support regulatory decision-making, and help clinics identify opportunities for quality improvement. Multiple myeloma and SCD data are now being accepted. Learn about the Data Hub.

The SCD Clinical Trials Network (SCD Network) is fostering collaborative partnerships to accelerate progress in clinical research and improve outcomes for individuals living with SCD by expediting the development of therapeutics and generating high-quality evidence to support clinical decision-making. Learn about the SCD Network.

SCD research progress is impossible without the involvement of the SCD community. Visit the SCD Community page for information just for individuals with SCD, their loved ones, and advocates.


Latest Announcements

News & Events

Inaugural Members Appointed to ASH RC Board of Directors

The ASH Research Collaborative® (ASH RC) is proud to announce its Board of Directors, a diverse group of hematologists and data, health systems, and informatics experts committed to advancing critical research and accelerating positive change for people living with hematologic conditions. The ASH RC supports the overall mission of the American Society of Hematology (ASH) and is a supporting organization to the Society. 


Inaugural Members Appointed to ASH RC Board of Directors

ASH Research Collaborative and Reagan-Udall Foundation for the FDA Launch Sickle Cell Disease Real-World Data Project

The ASH Research Collaborative (ASH RC) and the Reagan-Udall Foundation for the Food and Drug Administration (FDA Foundation) are launching the Real-World Evidence Consortium for Sickle Cell Disease (SCD) to develop consensus recommendations on clinical outcomes important to treating people with SCD and apply those standards to real-world data sets.

ASHRC & Regan-Udall Foundation for FDA

ASH Research Collaborative & Regan-Udall Foundation for the Food and Drug Administration

Healio: Data registry to guide care for patients with COVID-19, blood cancers

ASH Research Collaborative’s Data Hub launched an international data registry to help inform care for individuals with blood cancers and COVID-19.

Healio: Hematology/Oncology

Healio: Hematology/Oncology

The Hematologist: Update on the ASH Research Collaborative Data Hub

Dr. William Wood provides an update on the Data Hub – ASH Research Collaborative’s shared information repository.

The Hematologist: ASH News & Reports

The Hematologist: ASH News & Reports

Inside a Patient Centered Approach to Treating Sickle Cell Disease

The ASH Research Collaborative’s Sickle Cell Disease (SCD) Clinical Trials Network (CTN) patient-centered approach was recently featured in Media Planet’s Clinical Trials issue. Learn more by reading the full story here.

MediaPlanet Clinical Trials

MediaPlanet Clinical Trials: November 20, 2019

Sickle Cell Disease Learning Community Launches

The American Society of Hematology and the ASH RC are happy to announce the launch of the Pilot Sickle Cell Disease Learning Community.  The Sickle Cell Disease Learning Community is focused on improving the care and outcomes of people living with Sickle Cell Disease through the adoption of evidence informed best practices.


American Society of Hematology & ASH Research Collaborative

GBT Supports the ASH Research Collaborative’s Data Hub Sickle Cell Disease Program

The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of Hematology (ASH), and Global Blood Therapeutics, Inc. (GBT) today announced that GBT will provide a grant of $400,000 to the ASH RC in support of the ASH RC Data Hub Sickle Cell Disease (SCD) program.

Global Blood Therapeutics - ASHRC

Global Blood Therapeutics & ASH Research Collaborative

Follow Us On Twitter/X